Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART

References

• Daar ES, Smith KY, Powderly WG. Long-term complications of HIV and antiretroviral therapy. Clin Care Opt 2012:1–18.
   Google Scholar
• Foca E, Motta D, Borderi M, Gotti D, Albini L, Calabresi A, et al. Prospective evaluation of bone markers, parathormone and 1.25-OH-2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. BMC Infect Dis 2012; 12:1–8.
   PubMedGoogle Scholar
• Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000;14:63–7.
   PubMed Web of Science ®Google Scholar
• Amiel C, Ostertag A, Slama L, Baudoin C, N’Guyen T, Lajeunie E, et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 2004;19:402–9.
   PubMed Web of Science ®Google Scholar
• Brown TT, Ruppe MD, Kassner R, Kumar P, Kehoe T, Dobs AS, et al. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab 2004;89:1200–6.
   PubMed Web of Science ®Google Scholar
• Brown TT, Qaquish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006;20:2165–74.
   PubMed Web of Science ®Google Scholar
• Yin MT, Kendall MA, Wu X, Tassiopoulos K, Hochberg M, Huang JS, et al. Fractures after antiretroviral initiation: an analysis of the ACTG longitudinal linked randomized trial (ALLRT) study. AIDS 2012;26:2175–84.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 2010;51:937–46.
   PubMed Web of Science ®Google Scholar
• Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008;22:395–402.
   PubMedGoogle Scholar
• Fernandez-Rivera J, Garcia R, Lozano F, Macías J, García-García JA, Mira JA, et al. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials 2003;4:337–46.
   PubMed Web of Science ®Google Scholar
• Rivas P, Gorgolas M, Garcia-Delgado R, Diaz-Curiel M, Goyenechea A, Fernandez-Guerrero ML. Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Med 2008;9:89–95.
   PubMed Web of Science ®Google Scholar
• Nolan D, Upton R, McKinnon E, John M, James I, Adler B, et al. Stable or increasing bone mineral density in HIV- infected patients treated with nelfinavir or indinavir. AIDS 2001;15:1275–80.
   PubMed Web of Science ®Google Scholar
• Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009;23:817–24.
   PubMed Web of Science ®Google Scholar
• Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J AIDS 2009;51:554–61.
   PubMed Web of Science ®Google Scholar
• Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48 week results from the ASSERT study. Clin Infect Dis 2010;51: 963–72.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011;203:1791–801.
   PubMed Web of Science ®Google Scholar
• Fardellone P, Sebert JL, Bouraya M, Bonidan O, Leclercq G, Doutrellot C, et al. Evaluation de la teneur en calcium du régime alimentaire par autoquestionnaire fréquentiel. Rev Rhum 1991;58:99–103.
   PubMedGoogle Scholar
• R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. 2011. Available from: http://www.R-project.org/.
   Google Scholar
• Grijsen ML, Vrouenraets SME, Steingrover R, Lips P, Reiss P, Wit FW, et al. High prevalence of reduced bone mineral density in primary HIV-1-infected men. AIDS 2010;24:2233–8.
   PubMed Web of Science ®Google Scholar
• Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, et al. Longitudinal evolution of bone mineral density and bone markers in human immuno-deficiency virus-infected individuals. Clin Infect Dis 2003;36:482–90.
   PubMed Web of Science ®Google Scholar
• Casado JL, Banon S, Andrés R, Perez-Elias MJ, Moreno A, Moreno S. Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV- infected patients. Osteoporos Int 2014;25:1071–9.
   PubMed Web of Science ®Google Scholar
• Grant PM, Kitch D, McComsey A, Dube MP, Haubrich R, Huang J, et al. Low baseline CD4 + count is associated with greater bone mineral density loss after ART initiation. Clin Infect Dis 2013;57:1483–8.
   PubMed Web of Science ®Google Scholar
• Negredo E, Domingo P, Ferrer E, Estrada V, Curran A, Navarro A, et al. Peak bone mass in young HIV-infected patients compared with healthy controls. J AIDS 2014;65:207–12.
   PubMed Web of Science ®Google Scholar
• Ofotokun I, McIntosh E, Weitzmann MN. HIV: inflammation and bone. Curr HIV/AIDS Rep 2012;9:16–25.
   PubMedGoogle Scholar
• Aydin OA, Karaosmanoglu HK, Karahasanoglu R, Tahmaz M, Nazlican O. Prevalence and risks factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients. Braz J Infect Dis 2013;17:707–11.
   PubMedGoogle Scholar
• Bolland MJ, Wang TK, Grey A, Gamble GD, Reid IR. Stable bone density in HAART-treated individuals with HIV: a meta-analysis. J Clin Endocrinol Metab 2011;96:2721–31.
   PubMedGoogle Scholar
• Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 2010;24:2827–33.
   PubMed Web of Science ®Google Scholar
• Haskelberg H, Hoy JF, Amin J, Ebeling PR, Emery S, Carr A, STEAL study group. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One 2012;7:e38377.
   PubMed Web of Science ®Google Scholar
• Assoumou L, Katlama C, Viard JP, Bentata M, Simon A, Roux C, et al. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. AIDS 2013;27:2425–30.
   PubMed Web of Science ®Google Scholar
• Martin A, Moore C, Mallon P, Hoy JF, Emery S, Belloso W, et al. Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy. AIDS 2013;27:2403–11.
   PubMed Web of Science ®Google Scholar
• Piso RJ, Rothen M, Rothen JP, Stahl M. Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used. J AIDS 2011;56:320–4.
   PubMedGoogle Scholar
• Brown TT, Ross AC, Storer N, Labbato D, McComsey GA. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Antivir Ther 2011;16:1063–72.
   PubMed Web of Science ®Google Scholar